Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
This article was originally published in The Pink Sheet Daily
Executive Summary
NEJM article points to much higher bleeding with no compensatory efficacy in failed APPRAISE-2 add-on trial with apixaban.